NYSEAMERICAN:BPMX Biopharmx (BPMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Biopharmx Stock (NYSEAMERICAN:BPMX) Get Biopharmx alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume336,508 shsAverage Volume2.15 million shsMarket Capitalization$111.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioPharmX Corporation was a clinical-stage pharmaceutical company focused on developing topical treatments for dermatological conditions. Its research included products based on HyaloSphere, a proprietary drug-delivery technology using hyaluronic acid.The company’s pipeline included BPX-01, a topical minocycline gel being developed for acne, and BPX-04, a topical minocycline candidate for rosacea. These products were in development rather than marketed treatments.In 2019, BioPharmX merged with Timber Pharmaceuticals, and the combined company adopted the Timber Pharmaceuticals name.AI Generated. May Contain Errors. Read More Receive BPMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMX Stock News HeadlinesBioPharmX (BPMX) Stock Soars on Potential 'Breakthrough' Acne TreatmentJuly 8, 2023 | thestreet.comForm 424B5 Timber Pharmaceuticals, - StreetInsider.comOctober 3, 2022 | streetinsider.comSomething Strange Is Happening In MiamiOn December 14, President Trump will host leaders of the world's largest economies at his private Miami resort, with China's Xi Jinping expected to attend. Porter Stansberry believes the gathering could mark the unveiling of a new dollar. He argues that the tariffs, the war in Iran, and government stakes in mining companies all connect to a plan to reset the dollar. Foreign holdings of U.S. Treasuries climbed to a record high this year after years of selling. His briefing covers his No. 1 move and the companies at the center of it. | Porter & Company (Ad)Outlook on the Acne Treatment Global Market, to 2027 - Rising Public Knowledge of Cosmetic Acne Treatments is Driving Growth - Yahoo FinanceSeptember 22, 2022 | finance.yahoo.comGlobal Acne Treatment Market, By Therapeutic Class, By Formulation, By Type, By Acne Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 - GlobeNewswireJuly 19, 2022 | globenewswire.comTimber Pharmaceuticals, Inc. (TMBR) Stock Price Today, Quote & News - Seeking AlphaJuly 17, 2022 | seekingalpha.comForm DEF 14A Vivos Therapeutics, Inc. For: Jul 14 - StreetInsider.comJuly 14, 2022 | streetinsider.comManagement's Discussion and Analysis of the Results of Operations - Marketscreener.comMay 13, 2022 | marketscreener.comMSee More Headlines BPMX Stock Analysis - Frequently Asked Questions How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) posted its quarterly earnings data on Tuesday, December, 10th. The biotechnology company reported ($1.68) EPS for the quarter, topping the consensus estimate of ($2.64) by $0.96. When did Biopharmx's stock split? Biopharmx shares reverse split on the morning of Tuesday, May 19th 2020.The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Biopharmx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biopharmx investors own include Novavax (NVAX), TNF Pharmaceuticals (TNFA), Jaguar Animal Health (JAGX), Atossa Genetics (ATOS), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX) and Micron Technology (MU). Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CIKN/A Webwww.biopharmx.com Phone+1-650-8895020FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,278,000Free FloatN/AMarket Cap$111.86 million OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and GoogleCould the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.Get This Free Report This page (NYSEAMERICAN:BPMX) was last updated on 5/18/2020 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biopharmx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Biopharmx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.